SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Hong Zhao sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $330,000.00. Following the sale, the chief executive officer now owns 30,000 shares of the company’s stock, valued at approximately $330,000. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of SciClone Pharmaceuticals, Inc. (SCLN) traded down 0.45% during mid-day trading on Wednesday, hitting $11.00. 419,627 shares of the stock traded hands. SciClone Pharmaceuticals, Inc. has a one year low of $8.55 and a one year high of $11.43. The stock has a market cap of $574.10 million, a PE ratio of 13.56 and a beta of 1.71. The stock has a 50-day moving average of $10.98 and a 200 day moving average of $10.16.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The company had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. Equities analysts predict that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Hong Zhao Sells 30,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/16/hong-zhao-sells-30000-shares-of-sciclone-pharmaceuticals-inc-scln-stock.html.

Several institutional investors have recently added to or reduced their stakes in SCLN. Piedmont Investment Advisors LLC acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $123,000. Susquehanna International Group LLP acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $142,000. The Manufacturers Life Insurance Company boosted its position in SciClone Pharmaceuticals by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 41,284 shares of the specialty pharmaceutical company’s stock valued at $454,000 after buying an additional 1,459 shares during the period. Cubist Systematic Strategies LLC acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $195,000. Finally, GLG Partners LP boosted its position in SciClone Pharmaceuticals by 337.5% in the second quarter. GLG Partners LP now owns 1,588,897 shares of the specialty pharmaceutical company’s stock valued at $17,478,000 after buying an additional 1,225,709 shares during the period. Institutional investors own 73.26% of the company’s stock.

Separately, Maxim Group set a $14.00 price objective on shares of SciClone Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 11th.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.